Finance

Lists
UTHR:NASDAQ
United Therapeutics Corp
၅၃၀.၂၉ US$
+၂.၆၃%
(+၁၃.၆၁) 1D
ဩ ၂၇, GMT-၄ ၁၄:၄၁:၂၆  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for UTHR...
Open
၅၁၃.၉၈ US$
High
၅၃၁.၇၆ US$
Low
၅၁၁.၀၀ US$
Mkt. cap
ဋေ ၂.၂၇ ထ
Avg. vol.
၄.၉၂ သိန်း
Volume
၁.၇၆ သိန်း
P/E ratio
၁၈.၉၇
52-wk high
၆၀၉.၃၅ US$
52-wk low
၃၀၂.၁၉ US$
EPS
၂၇.၉၆ US$
Beta
၀.၅၉
Shares outstanding
၄.၂၉ ကုဋေ
No. of employees
၁ ထောင်
Open
၅၁၃.၉၈ US$
High
၅၃၁.၇၆ US$
Low
၅၁၁.၀၀ US$
Mkt. cap
ဋေ ၂.၂၇ ထ
Avg. vol.
၄.၉၂ သိန်း
Volume
၁.၇၆ သိန်း
P/E ratio
၁၈.၉၇
52-wk high
၆၀၉.၃၅ US$
52-wk low
၃၀၂.၁၉ US$
EPS
၂၇.၉၆ US$
Beta
၀.၅၉
Shares outstanding
၄.၂၉ ကုဋေ
No. of employees
၁ ထောင်
News stories
From web sources and news partners
Stock Titan
Stock Titan
·
ပြီးခဲ့သည့် ၂၂ နာရီ
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၁ ရက်
United Therapeutics (UTHR) Faces A Valuation Test After FDA Accepts Ralinepag NDA
www.marketscreener.com
www.marketscreener.com
·
ပြီးခဲ့သည့် ၁ ရက်
United Therapeutics Insider Sold Shares Worth $4,863,730, According to a Recent SEC Filing
GuruFocus
GuruFocus
·
ပြီးခဲ့သည့် ၃ ရက်
UTHR Looks 20.2% Overvalued on GF Value™ as FDA Accepts Ralinepa
Profile
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire. Wikipedia
About United Therapeutics Corp
CEO-
Employees၁.၄ ထောင်
Founded၁၉၉၆
HeadquartersSilver Spring, မေရီလန်းပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websiteunither.com
Analyst ratings
Based on 9 analysts giving stock ratings to UTHR in the past 3 months
Strong buy
Buy
7
Hold
2
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for UTHR in the last 3 months.
Highest
Current ၅၃၀.၂၉ US$
၇၁၄.၀၀ US$ (+၃၄.၆၄%)
Average
၆၅၅.၁၃ US$ (+၂၃.၅၄%)
Lowest
၅၁၅.၀၀ US$ (-၂.၈၈%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lisa Walter
RBC Capital
Buy
Maintained
၆၇၇.၀၀ US$
+၂၇.၇%
08/25/2026
Joseph Thome
TD Cowen
Buy
Maintained
၆၇၅.၀၀ US$
+၂၇.၃%
08/24/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
၇၀၀.၀၀ US$
+၃၂%
08/19/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
၆၆၀.၀၀ US$
+၂၄.၅%
08/06/2026
Terence Flynn
Morgan Stanley
Hold
Reiterated
၅၁၅.၀၀ US$
-၂.၉%
08/06/2026
Jessica Fye
J.P. Morgan
Buy
Maintained
၆၈၇.၀၀ US$
+၂၉.၆%
07/23/2026
Roger Song
Jefferies
Buy
Maintained
၇၁၄.၀၀ US$
+၃၄.၆%
07/10/2026
Jason Gerberry
Bank of America Securities
Hold
Reiterated
၆၁၃.၀၀ US$
+၁၅.၆%
07/10/2026
Roanna Ruiz
Leerink Partners
Buy
Maintained
-
-
06/29/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
၆၈၅.၀၀ US$
+၂၉.၂%
05/20/2026
Unknown Analyst
Raymond James
Buy
Initiated
၇၀၀.၀၀ US$
+၃၂%
04/09/2026
Tiago Fauth
Raymond James
Buy
Initiated
၇၀၀.၀၀ US$
+၃၂%
04/09/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
၆၅၀.၀၀ US$
+၂၂.၆%
03/12/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Initiated
၆၂၅.၀၀ US$
+၁၇.၉%
03/12/2026
Ashwani Verma
UBS
Buy
Reiterated
၇၀၅.၀၀ US$
+၃၂.၉%
03/05/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
၅၆၀.၀၀ US$
+၅.၆%
03/03/2026
Julian Harrison
BTIG
Hold
Maintained
-
-
02/25/2026
Last report
၂၀၂၆ ဩ ၅
Fiscal period
Q2 2026
EPS / Est. (USD)
၇.၂၇ US$ / ၇.၀၃ US$
+၃.၄၇%beat
Revenue / Est. (USD)
၇၈.၃၃ ကုဋေ / ၈၀.၄၆ ကုဋေ
-၂.၆၅%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၇၉.၉၅ ကုဋေ
၇၉.၀၂ ကုဋေ
၇၈.၁၅ ကုဋေ
၇၈.၃၃ ကုဋေ
Cost of goods sold
၁၀.၀၉ ကုဋေ
၁၀.၃၄ ကုဋေ
၁၃.၃၄ ကုဋေ
၉.၉၅ ကုဋေ
Cost of revenue
၁၀.၀၉ ကုဋေ
၁၀.၃၄ ကုဋေ
၁၃.၃၄ ကုဋေ
၉.၉၅ ကုဋေ
Research and development expenses
၁၂.၇၅ ကုဋေ
၁၃.၉၅ ကုဋေ
၁၃.၈၂ ကုဋေ
၁၄.၆၃ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁၈.၁၈ ကုဋေ
၁၈.၉၉ ကုဋေ
၁၈.၄၁ ကုဋေ
၂၀.၆၇ ကုဋေ
Operating expense
၃၀.၉၃ ကုဋေ
၃၂.၉၄ ကုဋေ
၃၂.၂၃ ကုဋေ
၃၅.၃၀ ကုဋေ
Total operating expenses
၄၁.၀၂ ကုဋေ
၄၃.၂၈ ကုဋေ
၄၅.၅၇ ကုဋေ
၄၅.၂၅ ကုဋေ
Operating income
၃၈.၉၃ ကုဋေ
၃၅.၇၄ ကုဋေ
၃၂.၅၈ ကုဋေ
၃၃.၀၈ ကုဋေ
Other non operating income
၃.၀၀ သိန်း
၈.၀၀ သိန်း
၁.၅၃ ကုဋေ
-၁.၀၀ သိန်း
EBT including unusual items
၄၃.၈၀ ကုဋေ
၄၄.၄၀ ကုဋေ
၃၁.၈၃ ကုဋေ
၃၇.၂၇ ကုဋေ
EBT excluding unusual items
၄၃.၃၀ ကုဋေ
၃၉.၈၃ ကုဋေ
၃၇.၉၉ ကုဋေ
၃၅.၉၃ ကုဋေ
Income tax expense
၉.၉၃ ကုဋေ
၇.၉၇ ကုဋေ
၄.၃၄ ကုဋေ
၃.၉၇ ကုဋေ
Effective tax rate
၂၂.၆၇%
၁၇.၉၅%
၁၃.၆၃%
၁၀.၆၅%
Other operating expenses
-
-
-
-
Net income
၃၃.၈၇ ကုဋေ
၃၆.၄၃ ကုဋေ
၂၇.၄၉ ကုဋေ
၃၃.၃၀ ကုဋေ
Net profit margin
၄၂.၃၆%
၄၆.၁၀%
၃၅.၁၈%
၄၂.၅၁%
Earnings per share
၇.၁၆
၇.၇၀
၅.၈၂
၇.၂၇
Interest and investment income
၄.၆၄ ကုဋေ
၄.၃၂ ကုဋေ
၄.၁၈ ကုဋေ
၃.၁၅ ကုဋေ
Interest expense
-၃.၀၀ သန်း
-၃.၁၀ သန်း
-၃.၀၀ သန်း
-၂.၉၀ သန်း
Net interest expenses
၄.၃၄ ကုဋေ
၄.၀၁ ကုဋေ
၃.၈၈ ကုဋေ
၂.၈၆ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၄၁.၁၂ ကုဋေ
၃၈.၀၂ ကုဋေ
၃၄.၈၄ ကုဋေ
၃၅.၅၀ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google အက်ပ်များ